Genetic heterogeneity of hypervariable region 1 of the hepatitis C virus (HCV) genome and sensitivity of HCV to alpha interferon therapy

Journal of Virology

Volumn 74, Issue 2, 2000, Pages 661-668

  Sandres, K ^a,b   Dubois, M ^a   Pasquier, C ^a   Payen, J L ^a   Alric, L ^a   Duffaut, M ^a   Vinel, J P ^a   Pascal, J P ^a   Puel, J ^a   Izopet, J ^a  

^a CHU PURPAN   (France)

^b TOULOUSE UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; AMINO ACID; NUCLEOTIDE; VIRUS RNA;

ADULT; AMINO ACID SEQUENCE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENETIC HETEROGENEITY; HEPATITIS B; HEPATITIS C VIRUS; HUMAN; IMMUNE RESPONSE; MALE; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; VIRUS GENOME;

ADULT; AMINO ACID SEQUENCE; ANTIVIRAL AGENTS; BASE SEQUENCE; DNA, VIRAL; FEMALE; GENETIC HETEROGENEITY; GENOME, VIRAL; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; RETROSPECTIVE STUDIES; SEQUENCE HOMOLOGY, AMINO ACID; VIRAL ENVELOPE PROTEINS;

EID: 0033986414     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.74.2.661-668.2000     Document Type: Article

References (61)

1. Alter, H., R. Purcell, J. Shih, J. Melpolder, M. Houghton, Q. Choo, and G. Kuo. 1989. Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis. N. Engl. J. Med. 321:1494-1500.
2. Causse, X., H. Godinot, M. Chevallier, P. Chossegros, F. Zoulim, and D. Ouzan. 1991. Comparison of 1 or 3 MU of interferon alpha-2b and placebo in patients with chronic non-A, non-B hepatitis. Gastroenterology 101:497-502.
3. Chayama, K., A. Tsubota, Y. Arase, S. Saitoh, K. Ikeda, T. Matsumoto, M. Hashimoto, M. Kobayashi, M. Kanda, T. Morinaga, and H. Kumada. 1995. Genotype, slow decrease in virus titer during interferon treatment and high degree of sequence variability of hypervariable region are indicative of poor response to interferon treatment in patients with chronic hepatitis type C. J. Hepatol. 23:684-553.
4. Chayama, K., A. Tsubota, M. Kobayashi, K. Okamoto, M. Hashimoto, Y. Miyano, H. Koibe, M. Kobayashi, I. Koida, Y. Arase, S. Saitoh, Y. Suzuki, N. Murashima, K. Ikeda, and H. Kumada. 1997. Pretreatment virus load and multiple amino acid substitutions in the interferon sensitivity-determining region predict the outcome of interferon treatment in patients with chronic genotype 1b hepatitis C virus infection. Hepatology 25:745-749.
5. Choo, Q., G. Kuo, A. Weiner, L. Overby, D. Bradley, and M. Houghton. 1989. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 244:359-362.
6. Davis, G., L. Balart, E. Schiff, K. Lindsay, H. Bodenheimer, R. Perrillo, W. Carey, I. Jacobson, J. Payne, J. Dienstag, D. Van Thiel, C. Tamburro, J. Lefkowitch, J. Albrecht, C. Meschievitz, T. Ortego, and A. Gibas. 1989. Treatment of chronic hepatitis C with recombinant interferon alpha. A multicentre randomized, controlled trial. The Hepatitis Interventional Therapy Group. N. Engl. J. Med. 12:1501-1505.
7. Davis, G., R. Esteban-Mur, V. Rustgi, J. Hoefs, S. C. Gordon, C. Trepo, M. L. Shiffman, S. Zeuzem, A. Craxi, M. H. Ling, and J. Albrecht. 1998. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. N. Engl. J. Med. 339:1493-1499.
8. Domingo, E. 1996. Biological significance of viral quasispecies. Viral Hepat. Rev. 2:247-261.
9. Enomoto, N., I. Sakuma, Y. Asahina, M. Kurosaki, T. Murakami, C. Yamamoto, N. Izumi, F. Marumo, and C. Sato. 1995. Comparison of full-length sequences of interferon-sensitive and resistant hepatitis C virus lb. Sensitivity to interferon is conferred by amino acid substitutions in the NS5A region. J. Clin. Investig. 96:224-230.
10. Enomoto, N., I. Sakuma, Y. Asahina, M. Kurosaki, T. Murakami, C. Yamamoto, Y. Ogura, N. Izumi, F. Marumo, and C. Sato. 1996. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus lb infection. N. Engl. J. Med. 334:77-81.
11. Farci, P., H. Alter, D. Wong, R. Miller, S. Govindarajan, R. Engle, M. Shapiro, and R. Purcell. 1994. Prevention of hepatitis C virus infection in chimpanzees after antibody-mediated in vitro neutralization. Proc. Natl. Acad. Sci. USA 91:7792-7796.
12. Frasca, M., P. Del Porto, L. Tuoslo, B. Marinari, C. Scotia, M. Carbonari, A. Nicosia, and E. Piccolella. 1999. Hypervariable region 1 variants act as TCR antagonists for hepatitis C virus-specific CD4+ T cells. J. Immunol. 163:650-658.
13. Gale, M., M. Korth, N. Tang, S. Tan, D. Hopkins, T. Dever, S. Polyak, D. Gretch, and M. Katze. 1997. Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein. Virology 230:217-227.
14. Gale, M., Jr., B. Kwieciszewski, M. Dossett, H. Nakao, and M. G. Katze. 1999. Antiapoptotic and oncogenic potentials of hepatitis C virus are linked to interferon resistance by viral repression of the PKR protein kinase. J. Virol. 73:6506-6516.
15. Gretch, D., and S. Polyak. 1997. The quasispecies nature of hepatitis C virus: research methods and biological implications, p. 57-69. In J. L. Eurotext (ed.), Hepatitis C virus: genetic heterogeneity and viral load. Groupe Français d'Etudes Moléculaires des Hépatites (GEMHEP), Paris, France.
16. Gretch, D., S. Polyak, J. Wilson, R. Carithers, J. Perkins, and L. Corey. 1996. Tracking hepatitis C virus quasispecies major and minor variants in symptomatic and asymptomatic liver transplant recipients. J. Virol. 70:7622-7631.
17. Hagiwara, H., N. Hayashi, E. Mita, T. Takehara, A. Kasahara, H. Fusamoto, and T. Kamada. 1993. Quantitative analysis of hepatitis C virus RNA in serum during interferon alpha therapy. Gastroenterology 104:877-883.
18. Hijikata, M., N. Kato, Y. Ootsuyama, M. Nakagawa, and K. Shimotohno. 1991. Gene mapping of the putative structural region of the hepatitis C virus genome by in vitro processing analysis. Proc. Natl. Acad. Sci. USA 88:5547-5551.
19. Holland, J., J. De La Torre, and D. Steinhauer. 1992. RNA virus populations as quasispecies. Curr. Top. Microbiol. Immunol. 176:1-20.
20. Hoofnagle, J., and A. Di Bisceglie. 1997. The treatment of chronic viral hepatitis. N. Engl. J. Med. 336:347-356.
21. Hoofnagle, J., and D. Lau. 1996. Chronic viral hepatitis-benefits of current therapies. N. Engl. J. Med. 334:14711-1471.
22. Izopet, J., J. Payen, L. Alric, K. Sandres, J. Charlet, J. Vinel, M. Duffaut, J. Pascal, and J. Puel. 1998. Baseline level and early suppression of serum HCV RNA for predicting sustained response to alpha-interferon therapy. J. Med. Virol. 54:86-91.
23. Jouet, P., F. Roudot-Thoraval, D. Dhumeaux, and J. Metreau. 1994. Comparative efficacy of interferon alpha in cirrhotic and noncirrhotic patients with non-A. non-B,C hepatitis. Gastroenterology 106:686-690.
24. Jukes, T. H., and T. R. Cantor. 1969. Evolution of protein molecules, p. 21-132. In I. H. N. Munro (ed.), Mammalian protein metabolism. Academic Press, Inc., New York, N. Y.
25. Kanazawa, Y., N. Hayashi, E. Mita, T. Li, H. Hagiwara, A. Kasahara, H. Fusamoto, and T. Kamada. 1994. Influence of viral quasispecies on effectiveness of interferon therapy in chronic hepatitis C patients. Hepatology 20:1121-1130.
26. Khorsi, H., S. Castelain, A. Wyseur, J. Izopet, V. Canva, A. Rombout, D. Capron, J. Capron, F. Lunel, L. Stuyver, and G. Duverlie. 1997. Mutations of hepatitis C virus 1b NS5A 2209-2248 amino acid sequence do not predict the response to recombinant interferon-alpha therapy in French patients. J. Hepatol. 27:72-77.
27. Knodell, K., K. Ishak, W. Black, T. Chen, R. Craig, and N. Kaplowitz. 1981. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 5:431-435.
28. Koch, J. O., and R. Bartenschlager. 1999. Modulation of hepatitis C virus NS5A hyperphosphorylation by nonstructural proteins NS3, NS4A, and NS4B. J. Virol. 73:7138-7146.
29. Koizumi, K., N. Enomoto, M. Kurosaki, T. Murakami, N. Izumi, F. Marumo, and C. Sato. 1995. Diversity of quasispecies in various disease stages of chronic hepatitis C virus infection and its significance in interferon treatment. Hepatology 22:30-35.
30. Kumar, S., K. Tamura, and M. Nei. 1993. MEGA: molecular evolutionary genetic analysis for microcomputers. Comput. Appl. Biosci. 10:189-191.
31. Le Guen, B., G. Squadrito, B. Nalpas, P. Berthelot, S. Pol, and C. Brechot. 1997. Hepatitis C virus genome complexity correlates with response to interferon therapy: a study in French patients with chronic hepatitis C. Hepatology 25:1250-1254.
32. Martell, M., J. Esteban, J. Quer, J. Genesca, A. Weiner, R. Esteban, J. Guardia, and J. Gomez. 1992. Hepatitis C virus (HCV) circulates as a population of different hut closely related genomes: quasispecies nature of HCV genome distribution. J. Virol. 66:3225-3229.
33. Martinot-Peignoux, M., P. Marcellin, M. Pouteau, C. Castelnau, N. Boyer, M. Poliquin, C. Degott, I. Descombes, V. Le Breton, V. Milotova, J. Benhamou, and S. Erlinger. 1995. Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alfa therapy in chronic hepatitis C. Hepatology 22:1050-1056.
34. McHutchison, J. G., S. C. Gordon, E. R. Schiff, M. L. Shiffman, W. M. Lee, V. K. Rustgi, Z. D. Goodman, M. H. Ling, S. Cort, and J. K. Albrecht. 1998. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N. Engl. J. Med. 339:1485-1492.
35. Missale, G., E. Cariani, V. Lamonaca, A. Ravaggi, A. Rossini, R. Bertoni, M. Houghton, Y. Matsuura, F. Fiaccadori, and C. Ferrari. 1997. Effects of interferon treatment on the antiviral T-cell response in hepatitis C virus 1b-and genotype 2c-infected patients. Hepatology 26:792-797.
36. Moribe, T., N. Hayashi, Y. Kanazawa, E. Mita, H. Fusamoto, M. Negi, T. Kaneshige, H. Igimi, T. Kamada, and K. Uchida. 1995. Hepatitis C viral complexity detected by single-strand conformation polymorphism and response to interferon therapy. Gastroenterology 108:789-795.
37. Naito, M., N. Hayashi, T. Moribe, H. Hagiwara, E. Mita, Y. Kanazawa, A. Kasahara, H. Fusamoto, and T. Kamada. 1995. Hepatitis C viral quasispecies in hepatitis C virus carriers with normal liver enzymes and patients with type C chronic liver disease. Hepatology 22:407-412.
38. Nakazawa, T., N. Kato, S. Ohkoshi, A. Shibuya, and K. Shimotohno. 1994. Characterization of the 5′ noncoding and structural region of the hepatitis C virus genome from patients with non-A, non-B hepatitis responding differently to interferon treatment. J. Hepatol. 20:623-629.
39. Nelson, D., C. Marousis, T. Ohno, G. Davis, and J. Lau. 1998. Intrahepatic hepatitis C virus-specific cytotoxic T lymphocyte activity and response to interferon alfa therapy in chronic hepatitis C. Hepatology 28:225-230.
40. Neumann, A., N. Lam, H. Dahari, D. Grecht, T. Wiley, T. Layden, and A. Perelson. 1998. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon alfa therapy. Science 282:103-107.
41. Okada, S., Y. Akahane, H. Suzuki, H. Okamoto, and S. Mishiro. 1992. The degree of variability in the amino terminal region of the E2/NS1 protein of hepatitis C virus correlated with responsiveness to interferon therapy in viremic patients. Hepatology 16:619-624.
42. Pawlotsky, J., G. Germanidis, P. Frainais, M. Bouvier, A. Soulier, M. Pellerin, and D. Dhumeaux. 1999. Evolution of the hepatitis C virus second envelope protein hypervariable region in chronically infected patients receiving alpha interferon therapy. J. Virol. 73:6490-6499.
43. Pawlotsky, J., G. Germanidis, A. Neumann, M. Pellerin, P. Frainais, and D. Dhumeaux. 1998. Interferon resistance of hepatitis C virus genotype 1b: relationship to nonstructural 5a gene quasispecies mutations. J. Virol. 72: 2795-2805.
44. Pawlotsky, J., M. Pellerin, M. Bouvier, F. Roudot-Thoraval, G. Germanidis, A. Bastie, F. Darthuy, J. Remire, C. Soussy, and D. Dhumeaux. 1998. Genetic complexity of the hypervariable region 1 (HVR1) of hepatitis C virus (HCV): influence on the characteristics of the infection and responses to interferon alfa therapy in patients with chronic hepatitis C. J. Med. Virol. 54:256-264.
45. Polyak, S., G. Faulkner, R. Carithers, L. Corey, and D. Gretch. 1997. Assessment of hepatitis C virus quasispecies heterogeneity by gel shift analysis: correlation with response to interferon therapy. J. Infect. Dis. 175:1101-1107.
46. Polyak, S., S. McArdle, S. Liu, D. Sullivan, M. Chung, W. Hofgartner, R. J. Carithers, B. McMahon, J. Mullins, L. Corey, and D. Grecht. 1998. Evolution of hepatitis C virus quasispecies in hypervariable region 1 and the putative interferon sensitivity-determining region during interferon therapy and natural infection. J. Virol. 72:4288-4296.
47. Poynard, T., P. Marcellin, S. S. Lee, C. Niederau, G. S. Minuk, G. Ideo, V. Bain, J. Heathcote, S. Zeuzem, C. Trepo, and J. Albrecht. 1998. Randomised trial of interferon alpha 2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha 2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group. Lancet 352:1426-1432.
48. Qian, C., J. Camps, M. Maluenda, M. Civeira, and J. Prieto. 1992. Replication of hepatitis C virus in peripheral blood mononuclear cells. Effect of alpha-interferon therapy. J. Hepatol. 16:380-383.
49. Saiz, J., F. Lopez-Labrador, S. Ampurdanes, J. Dopazo, X. Forns, J. Sanchez-Tapias, and J. Rodes. 1998. The prognostic relevance of the non-structural 5A gene interferon sensitivity determining region is different in infections with genotype 1b and 3a isolates of hepatitis C virus. J. Infect. Dis. 177:839-847.
50. Shimizu, Y., M. Hiyikata, A. Iwamoto, H. Alter, R. Purcell, and H. Yoshikura. 1994. Neutralizing antibodies against hepatitis C virus and the emergence of neutralization escape mutant viruses. J. Virol. 68:1494-1500.
51. Shimizu, Y. K., H. Igarashi, T. Kiyohara, T. Cabezon, P. Farci, and R. H. Purcell. 1996. A hyperimmune serum against a synthetic peptide corresponding to the hypervariable region 1 of hepatitis C virus can prevent viral infection in cell cultures. Virology 223:409-412.
52. Shirai, M., T. Arichi, M. Chen, M. Nishioka, K. Ikeda, H. Takahashi, N. Enomoto, T. Saito, M. E. Major, T. Nakazawa, T. Akatsuka, S. M. Feinstone, and J. A. Berzofsky. 1999. T cell recognition of hypervariable region-1 from hepatitis C virus envelope protein with multiple class II MHC molecules in mice and humans: preferential help for induction of antibodies to the hypervariable region. J. Immunol. 162:568-576.
53. Squadrito, G., F. Leone, M. Sartori, B. Nalpas, P. Berthelot, G. Raimondo, S. Pol, and C. Brechet. 1997. Mutations in the nonstructural 5A region of hepatitis C virus and response of chronic hepatitis C to interferon alfa. Gastroenterology 113:567-572.
54. Tan, S. L., H. Nakao, Y. He, S. Vijaysri, P. Neddermann, B. L. Jacobs, B. J. Mayer, and M. G. Katze. 1999. NS5A, a nonstructural protein of hepatitis C virus, binds growth factor receptor-bound protein 2 adaptor protein in a Src homology 3 domain/ligand-dependent manner and perturbs mitogenic signaling. Proc. Nail. Acad. Sci. USA 96:5533-5558.
55. Taylor, D. R., S. T. Shi, P. R. Romano, G. N. Barber, and M. M. Lai. 1999. Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein. Science 285:107-109.
56. Wang, Y., S. Ray, O. Laeyendecker, J. Ticehurst, and D. Thomas. 1998. Assessment of hepatitis C virus sequence complexity by electrophoretic mobilities of both single-and double-stranded DNAs. J. Clin. Microbiol. 36:2982-2989.
57. Weiner, A. J., H. M. Geysen, C. Christopherson, J. E. Hall, T. J. Mason, G. Saracco, F. Bonino, K. Crawford, C. D. Marion, K. A. Crawford, M. Brunetto, P. Barr, M. T. J. McHutchinson, and M. Houghton. 1992. Evidence for immune selection of hepatitis C virus (HCV) putative envelope glycoprotein variants: potential role in chronic HCV infections. Proc. Natl. Acad. Sci. USA 89:3468-3472.
58. Wolinsky, S. M., B. T. M. Korber, A. U. Neumann, M. Daniels, K. J. Kunstman, A. J. Whestell, M. R. Furtado, Y. Cao, D. D. Ho, J. T. Safrit, and R. A. Koup. 1996. Adaptive evolution of human immunodeficiency virus-type 1 during the natural course of infection. Science 272:537-542.
59. Yoshioka, K., T. Aiyama, A. Okumura, M. Takayanagi, K. Iwata, T. Ishikawa, Y. Nagai, and S. Kakumu. 1997. Humoral immune response to the hypervariable region of hepatitis C virus differs between genotypes 1b and 2a. J. Infect. Dis. 175:505-510.
60. Zeuzem, S., J. Lee, and W. Roth. 1997. Mutations in the nonstructural 5A gene of European hepatitis C virus isolates and response to interferon alfa. Hepatology 25:740-744.
61. Zibert, A., E. Schreier, and M. Roggendorf. 1995. Antibodies in human sera specific to hypervariable region 1 of hepatitis C virus can block viral attachment. Virology 208:653-661.